Trials / Completed
CompletedNCT02843061
Combination of Rituximab and NK Immunotherapy for B Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
Detailed description
By enrolling patients with B lymphoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Rituximab and natural killer (NK) cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | |
| BIOLOGICAL | NK immunotherapy | Each time 10 billion cells, 4 times in all,i.v. |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-07-01
- Completion
- 2019-07-01
- First posted
- 2016-07-25
- Last updated
- 2019-09-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02843061. Inclusion in this directory is not an endorsement.